What is the recommended management for viral myocarditis?

Management of Viral Myocarditis

All patients with definite viral myocarditis must be hospitalized at an advanced heart failure center and initiated on guideline-directed medical therapy for heart failure, with immunosuppression reserved only for specific high-risk scenarios including fulminant presentations, concurrent severe pneumonia, or biopsy-proven giant cell/eosinophilic subtypes. 1, 2

Immediate Hospitalization and Risk Stratification

• Admit every patient with confirmed myocarditis to an advanced heart failure center for continuous cardiac monitoring to detect life-threatening arrhythmias early. 1, 2
• Transfer fulminant cases (cardiogenic shock, sustained ventricular tachyarrhythmias, high-grade AV block) immediately to facilities with mechanical circulatory support capability (veno-arterial ECMO) and cardiac transplant services. 1, 2
• Fulminant myocarditis carries 28% mortality at 60 days despite aggressive treatment, but survivors have better long-term prognosis than non-fulminant forms. 2

Diagnostic Work-Up

Mandatory Initial Testing

• Obtain 12-lead ECG immediately to identify ST-segment elevation without reciprocal depression, diffuse T-wave inversion, QRS prolongation, or complete/advanced AV block. 1, 3
• Measure high-sensitivity cardiac troponin; elevation occurs in approximately 90% of viral myocarditis cases, with marked elevation (>5× upper limit of normal) strongly suggesting myocarditis. 1, 3
• Perform transthoracic echocardiography to evaluate for left-ventricular wall-motion abnormalities following a non-coronary distribution and assess ejection fraction. 1, 3
• Request immediate cardiology consultation for rising troponin, concerning ECG changes, or echocardiographic wall-motion abnormalities. 1, 3

Advanced Imaging

• Perform cardiac MRI before hospital discharge in all hemodynamically stable patients with suspected myocarditis, ideally >10 days after symptom onset, to confirm myocardial inflammation and quantify ventricular dysfunction. 1, 2
• Reserve endomyocardial biopsy for cases where giant-cell myocarditis is suspected or when diagnosis remains uncertain despite CMR; typical viral myocarditis shows CD68+ macrophage/monocytic infiltration rather than diffuse lymphocytic infiltrates. 1, 2

Coronary Evaluation

• Perform coronary angiography only when type 1 myocardial infarction is suspected (anginal chest pain with ischemic ECG pattern). 1
• In patients >50 years (men) or >55 years (women), exclude flow-limiting coronary disease before confirming myocarditis. 1

Guideline-Directed Medical Therapy

• Initiate ACE-inhibitor/ARB, beta-blocker, and aldosterone antagonist (as appropriate) before discharge and titrate in outpatient follow-up. 1, 2, 3
• Use beta-blockers only when hemodynamically stable; they are beneficial for supraventricular arrhythmias but can precipitate cardiogenic shock in patients with compromised ventricular function. 1, 2
• Start low-dose aldosterone antagonist empirically in patients with mildly reduced left-ventricular systolic function and stable hemodynamics. 2, 3

Immunosuppressive Therapy: Three Specific Indications

Intravenous corticosteroids are indicated in only three scenarios: 1, 2

1. COVID-19 myocarditis with concurrent pneumonia requiring continuous supplemental oxygen 1
2. Hemodynamic compromise or multisystem inflammatory syndrome in adults (MIS-A) characterized by delayed-onset myocarditis, markedly elevated inflammatory biomarkers, high ferritin, and acute heart failure/cardiogenic shock without sepsis 1, 2
3. Fulminant myocarditis with biopsy-proven severe inflammatory infiltrates (giant cell myocarditis, cardiac sarcoidosis, eosinophilic myocarditis), after weighing the risk of secondary infection 1, 2

Special Considerations

• For immune checkpoint inhibitor-induced myocarditis, permanently discontinue immunotherapy and start high-dose methylprednisolone 1000 mg/day IV followed by oral prednisone 1 mg/kg/day. 2
• For high-grade myocarditis with hemodynamic instability not responding to corticosteroids, consider antithymocyte globulin, infliximab, mycophenolate mofetil, or abatacept. 2
• When symptoms improve rapidly, troponin normalizes, and left-ventricular function remains preserved, anti-inflammatory medication may be omitted. 1

Anti-Inflammatory Medications for Non-Fulminant Cases

• NSAIDs, colchicine, or corticosteroids may be employed for persistent chest pain or pericardial involvement. 1, 2
• Avoid NSAIDs in isolated myocarditis without pericardial involvement due to increased inflammation and mortality risk. 1
• Low-dose colchicine or short course of prednisone may be added for persistent chest pain, with gradual taper guided by symptoms. 2

Mechanical Circulatory Support

• Initiate mechanical circulatory support urgently if shock does not reverse rapidly with pharmacological therapy. 2
• Options include percutaneous cardiopulmonary support, ECMO, or intra-aortic balloon pump. 2

Arrhythmia Management

• Acute arrhythmias often resolve with resolution of inflammation; management is supportive. 2
• Insert temporary pacemaker if symptomatic bradycardia or high-grade AV block triggers ventricular tachyarrhythmias. 2, 3

Mandatory Activity Restriction

• Enforce complete exercise abstinence for 3-6 months after diagnosis; continued aerobic exercise during acute viral myocarditis increases mortality and sudden-death risk in animal models. 1, 2, 3
• Avoid competitive sport participation for 3-6 months. 2, 3

Return-to-Play Criteria at 3-6 Months

• Absence of cardiopulmonary symptoms 1
• Resolution of laboratory evidence of myocardial injury 1
• Normalization of LV systolic function 1
• Absence of spontaneous/inducible arrhythmias on ECG monitoring and exercise stress testing 1

Follow-Up Surveillance at 3-6 Months

• Perform comprehensive cardiac testing including ECG, transthoracic echocardiography, ambulatory rhythm monitoring, and repeat CMR to assess recovery, guide ongoing heart-failure management, and evaluate prognosis. 1, 2, 3
• Dilated cardiomyopathy develops in 21% of patients during long-term follow-up. 2

Prognosis

• The majority of patients with non-fulminant viral myocarditis experience symptom resolution and improvement in cardiac function, whether or not specific therapies are administered. 1
• Higher troponin levels correlate with worse clinical outcomes. 1, 3

Common Pitfalls to Avoid

• Do not use beta-blockers in hemodynamically unstable patients—they can precipitate cardiogenic shock. 1, 2
• Do not use NSAIDs for isolated myocarditis without pericardial involvement—they increase inflammation and mortality. 1
• Do not empirically immunosuppress all myocarditis patients—reserve for the three specific indications above to avoid secondary infection risk. 1, 2
• Do not allow patients to resume exercise before 3-6 months—premature activity increases sudden death risk. 1, 2